NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)

Active Not RecruitingN/A

Sponsor: AstraZeneca

Conditions: Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)

Countries: Japan

The purpose of the investigation is to confirm the followings under the post-marketing actual long-term use of Tezspire. 1. Development of related AEs 2. Contributing factors possibly having an impact on the safety and effectiveness 3. Development of unexpected related AEs

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* The evaluable patients are those treated with Tezspire for the first time due to "Bronchial asthma (only the patients with severe or intractable bronchial asthma which could not be controlled with the existing therapy)

Exclusion Criteria:

None

Locations (33)

Aichi, Japan
Akita, Japan
Aomori, Japan
Chiba, Japan
Fukui, Japan
Fukuoka, Japan
Gifu, Japan
Gunma, Japan
Hiroshima, Japan
Hokkaido, Japan
Hyōgo, Japan
Ibaraki, Japan
Ishikawa, Japan
Kagawa, Japan
Kanagawa, Japan
Kumamoto, Japan
Kyoto, Japan
Mie, Japan
Miyagi, Japan
Nara, Japan
Numakunai, Japan
Okayama, Japan
Osaka, Japan
Ōita, Japan
Saitama, Japan
Shimane, Japan
Shizuoka, Japan
Tochigi, Japan
Tokyo, Japan
Wakayama, Japan
+ 3 more on CT.gov